Cargando…

Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases

BACKGROUND: Bronchiectasis is frequently associated (up to 30%) with chronic inflammatory rheumatic diseases and leads to lower respiratory tract infections. Data are lacking on the risk of lower respiratory tract infections in patients treated with biologic agents. METHODS: Monocenter, retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geri, Guillaume, Dadoun, Sabrina, Bui, Tach, Del Castillo Pinol, Nuria, Paternotte, Simon, Dougados, Maxime, Gossec, Laure
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229465/ https://www.ncbi.nlm.nih.gov/pubmed/22046967 http://dx.doi.org/10.1186/1471-2334-11-304

Ejemplares similares

Methods to improve medication adherence in patients with chronic inflammatory rheumatic diseases: a systematic literature review
por: Lavielle, Matthieu, et al.
Publicado: (2018)

Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic
por: Dougados, Maxime
Publicado: (2021)

Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis
por: Gossec, Laure, et al.
Publicado: (2015)

Fatigue in Egyptian patients with rheumatic diseases: a qualitative study
por: Mortada, Mohamed, et al.
Publicado: (2015)

Relationship between optimism and quality of life in patients with two chronic rheumatic diseases: axial spondyloarthritis and chronic low back pain: a cross sectional study of 288 patients
por: Kreis, Sarah, et al.
Publicado: (2015)

Wearable Activity Trackers in the Management of Rheumatic Diseases: Where Are We in 2020?
por: Davergne, Thomas, et al.
Publicado: (2020)

Wearable activity trackers and artificial intelligence in the management of rheumatic diseases: Where are we in 2021?
por: Davergne, Thomas, et al.
Publicado: (2021)

Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID)
por: Dougados, Maxime, et al.
Publicado: (2012)

Tuberculosis in Children with Rheumatic Diseases Treated with Biologic Disease-Modifying Anti-Rheumatic Drugs
por: Kavadichanda, Chengappa, et al.
Publicado: (2021)

Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect?
por: Dougados, Maxime
Publicado: (2008)

Mobile Health Apps for Self-Management of Rheumatic and Musculoskeletal Diseases: Systematic Literature Review
por: Najm, Aurélie, et al.
Publicado: (2019)

EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases
por: Najm, Aurélie, et al.
Publicado: (2019)

Needs, Experiences, and Views of People With Rheumatic and Musculoskeletal Diseases on Self-Management Mobile Health Apps: Mixed Methods Study
por: Najm, Aurelie, et al.
Publicado: (2020)

The biology of pulmonary exacerbations in bronchiectasis
por: Amati, Francesco, et al.
Publicado: (2019)

Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study
por: Convertino, Irma, et al.
Publicado: (2021)

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2022)

An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis
por: Tenti, Sara, et al.
Publicado: (2023)

Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
por: Das, Priyam, et al.
Publicado: (2023)

Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
por: Hanaoka, Hironari, et al.
Publicado: (2022)

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
por: Michelena, Xabier, et al.
Publicado: (2020)

Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience
por: Migkos, Michalis P., et al.
Publicado: (2021)

Bronchiectasis—A Fatal Disease
por: Cookson, H. A., et al.
Publicado: (1938)

Is bronchiectasis really a disease?
por: Shteinberg, Michal, et al.
Publicado: (2020)

Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis
por: Nash, Peter, et al.
Publicado: (2021)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis
por: Choy, Ernest H
Publicado: (2019)

Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis
por: Min, Hong Ki, et al.
Publicado: (2022)

Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis
por: Kurata, Izumi, et al.
Publicado: (2019)

Prevalence of coronavirus disease 2019 in rheumatic patients and evaluation of the effect of disease-modifying anti-rheumatic drugs
por: Moradi, Soroush, et al.
Publicado: (2020)

Effectiveness of inactivated influenza vaccine in autoimmune rheumatic diseases treated with disease-modifying anti-rheumatic drugs
por: Nakafero, Georgina, et al.
Publicado: (2020)

Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs
por: Yousefghahari, Behnaz, et al.
Publicado: (2021)

Person-focused care for young people with rheumatic and musculoskeletal diseases: young rheumatologists' and EULAR Young PARE perspectives
por: Alunno, Alessia, et al.
Publicado: (2017)

Anti-Drug Antibodies in the Biological Therapy of Autoimmune Rheumatic Diseases
por: Pizano-Martinez, Oscar, et al.
Publicado: (2023)

Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients
por: Duarte, Catia, et al.
Publicado: (2021)

COVID-19 and Disease-Modifying Anti-rheumatic Drugs
por: D’Silva, Kristin M., et al.
Publicado: (2021)

Noncystic fibrosis bronchiectasis: Is it an orphan disease?
por: Mobaireek, Khalid F.
Publicado: (2007)

Bronchiectasis and Chronic Suppurative Lung Disease
por: Chang, Anne B., et al.
Publicado: (2019)

Monitoring disease progression in childhood bronchiectasis
por: Ramsey, Kathryn A., et al.
Publicado: (2022)

Comment on: BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs
por: Pakozdi, Angela, et al.
Publicado: (2017)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
por: Smolen, Josef S, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_s3rthgab8vh1r4592as469j4a4